Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy

• Main Authors: Asli Kavaz Tufan (Author), Fatma Ozak Batibay (Author), Gulsah Kaya Aksoy (Author), Bora Gulhan (Author), Beltinge Demircioglu Kilic (Author), Ismail Dursun (Author), Bahar Buyukkaragoz (Author), Aysun Caltik Yilmaz (Author), Hulya Nalcacioglu (Author), Tulay Becerir (Author), Nuran Cetin (Author), Kubra Celegen (Author), Meltem Dinleyici (Author), Mucahit Kaya (Author), Omer Kilic (Author), Ener Cagri Dinleyici (Author)
• Format: Book
• Published: MDPI AG, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background/Objectives: Eculizumab is a first-line treatment for atypical hemolytic uremic syndrome (aHUS), and patients undergoing eculizumab therapy may become more susceptible to infection caused by <i>Neisseria meningitidis</i> (<i>Nm</i>). While meningococcal vaccination...